Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Infections and infestations – page 39

  • 677 clinical trials
  • 261 recruiting
  • 278 conditions
  • 27 countries

Conditions in this area

278 conditions with trials, the busiest first

HIV infection75COVID-1939Pneumonia32Sepsis29Influenza28Respiratory syncytial virus infection20Post-acute COVID-19 syndrome19Septic shock17Urinary tract infection17Chronic hepatitis B16Bacterial infection14Hepatitis D14Cytomegalovirus infection13Appendicitis10Hepatitis B10Pneumonia bacterial10Fungal infection9Irritable bowel syndrome8Medical device site joint infection8Pyelonephritis acute7Staphylococcal bacteraemia7Staphylococcal infection7T-cell type acute leukaemia7Lower respiratory tract infection6+254

Clinical trials in Infections and infestations

677 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

677 clinical trials

Meningitis meningococcal

Not recruiting

Study on the Safety and Immune Response of MenABCWY Vaccine and Drug Combination in Healthy Infants with Meningococcal Infections

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000017986
  • Sponsor:GlaxoSmithKline Biologicals

Escherichia infection

Not recruiting

Study on Ciprofloxacin's Effect on Antibiotic Resistance in E. coli for Healthy Individuals

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ciprofloxacin
  • Sponsor:Institute Of Tropical Medicine

Influenza

Not recruiting

A Study of OVX836 Influenza Vaccine Given as Booster or Primary Vaccination in Healthy Adults Who Previously Received OVX836, Influenza Vaccine, or Placebo

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:INFLUENZA A (H1N1/WSN/1933) NUCLEOPROTEIN FUSED TO C-TERMINAL FRAGMENTS OF TWO AVIAN C4BP ALFA CHAIN SEQUENCES
  • Sponsor:OSIVAX Belgique

COVID-19

Not recruiting

Study on the Immune Response to Bretovameran COVID-19 mRNA Vaccine in Healthy Adults Aged 18-40

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:University Of Antwerp

Influenza

Not recruiting

Study on the Best Time for Influenza Vaccine Administration in Adults Aged 60-85 Using Influenza Vaccine and Drug Combination

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type)
  • Sponsor:Rijksinstituut voor Volksgezondheid en Milieu (RIVM)

Herpes simplex

Not recruiting

Study of HSV immunotherapy (HSVTI) for healthy adults aged 18-40 and people with recurrent genital herpes aged 18-60

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:GSKVX000000030810
  • Sponsor:GlaxoSmithKline Biologicals

Influenza

Not recruiting

Study Comparing High-Dose vs. Standard-Dose Influenza Vaccine for Preventing Flu in Older Adults

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years · Healthy volunteers
  • Substances:Elasomeran
  • Sponsor:Gentofte Hospital

COVID-19

Not recruiting

Study on the Safety and Immune Response of BIMERVAX as a COVID-19 Booster in Adolescents Aged 12 to 17 Years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · Healthy volunteers
  • Substances:SARS-COV-2 VIRUS, VARIANTS B.1.351-B.1.1.7, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HETERODIMER
  • Sponsor:Hipra Scientific S.L.

HIV infection

Not recruiting

Study on Lenacapavir for HIV Prevention in Individuals at Risk of HIV Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Emtricitabine
  • Sponsor:Gilead Sciences Inc.

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18-49 at Risk for Respiratory Syncytial Virus Compared to Adults 60 and Older

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Coronavirus infection

Not recruiting

Study on COVID-19 Prevention Using Sipavibart and Cilgavimab for Patients with Weakened Immune Systems

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Cilgavimab
  • Sponsor:AstraZeneca AB

Papilloma viral infection

Not recruiting

Study on the Effectiveness of the HPV Vaccine in Preventing HPV Infections in Men Who Have Sex with Men Aged 19-26 Using Cervarix

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN ADJUVANTED BY AS04 ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED PRODUCED ON BACULOVIRUS HI-5 RIX4446 CELLS, TRICHOPLUSIA NI. DERIVED
  • Sponsor:Geneeskundige En Gezondheidsdienst Amsterdam

Substances studied in this area

The therapies tested most often in Infections and infestations trials.

Sodium Chloride52 clinical trialsAmoxicillin35 clinical trialsEmtricitabine32 clinical trialsLinezolid32 clinical trialsTenofovir Alafenamide32 clinical trialsClavulanic Acid28 clinical trialsRifampicin25 clinical trialsSulfamethoxazole25 clinical trialsTrimethoprim25 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.